This document discusses UNITAID's strategy for HIV/AIDS testing, treatment, and prevention by 2020/2030. It outlines goals such as having 90% of people know their HIV status and 90% of infected people on antiretroviral therapy. The document then details UNITAID's current portfolio of projects supporting these goals, totaling over $300 million, which focus on early testing, treatment for children, and prevention. It argues that self-testing could help address market deficiencies and testing gaps, and that UNITAID funding now could stimulate the self-testing market and have public health impacts in low-and middle-income countries.

1. Page 1Page 1
HIV Self-testing in
global and UNITAID
strategy
Carmen Pérez-Casas
UNITAID
27, February, 2015
BMGF

2. Page 2
HIV-Monitoring
By 2020: 90% of people on ART virally supressed Current: < 30% access viral load
HIV-Treatment
By 2020: 90% of HIV-infected people on ART Current: 38% (24% for children)
HIV-Testing
By 2020: 90% of people know their HIV status Current: 50% (42% in children)
HIV Prevention
By 2030: 75% reduction in new infections,
zero new infant infections
Current: 2.1 m infected in 2013 (11,4% children)
Increased testing, key for targets achievement

3. Page 3
Investment on Self-testing within current HIV UNITAID
portfolio
HIV-Monitoring
MSF-CD4*/VL
($28.6m)
CHAI/UNICEF-
CD4*/VL ($35m)
FEI- VL
($6.2m)
Market entry projects: DRW VL ($8.4m), Daktari CD4* ($2.56m), Burnett CD4*
($1.6m); Wave 80 VL ; Cavidi VL ; MGH –TDF RDT
HIV-Treatment
DNDi-Paediatric ARVs
($17.3 m)
CHAI- Paediatric ARV market
($12.6 m)
Tides-Access to ARVs for MICs
($6m)
Medicines Patent Pool (current
extension $29m)
HIV-Testing
EGPAF Early Infant
Diagnosis ($63m)
Market entry: NWGHF ($3,7m);
DRW ($8.4 m EID/VL)
EID components in
CHAI/UNICEF & MSF projects
PSI Self-testing
($23 m for Phase I)
HIV Prevention
Need to increase number of people linked with prevention care (e.g. VMC and ARV-prevention methods such as PrEP) and with HIV care
(e.g. ART, also decreasing transmission rates)
Contribution to overarching projects, cofunding with other donors (BMGF):
WHO prequalification programe
(current extension for medicines $38m; diagnostic and devices $12m)

4. Page 4
All areas of cascade show market deficiencies;
severe market shortcomings for diagnostic tools
http://www.unitaid.eu/en/unitaid-market-dynamics-dashboard

5. Case for UNITAID‐support:
 Robust case made for UNITAID funding before general scale‐up of
the product and model can take place;
 High potential for public health impact and value for money by
decreasing current testing gap (complementing current models);
 Market effects could be delayed (price reduction, adaptability of
products for use in LMICs, quality assured suppliers) in the absence
of this timely investment.
Stimulating and shaping the market for HIV self-testing
in Africa
UNITAID/PSI HIV STAR Project
(UCL, LSTM, LHSTM and WHO)

6. THANK YOU FOR YOUR ATTENTION